ABBVIE INC (ABBV) Stock Fundamental Analysis

NYSE:ABBV • US00287Y1091

230.64 USD
+5.95 (+2.65%)
Last: Feb 27, 2026, 02:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to ABBV. ABBV was compared to 521 industry peers in the Biotechnology industry. Both the profitability and the financial health of ABBV get a neutral evaluation. Nothing too spectacular is happening here. ABBV has a bad growth rate and is valued cheaply. Finally ABBV also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ABBV had positive earnings in the past year.
  • In the past year ABBV had a positive cash flow from operations.
  • ABBV had positive earnings in 4 of the past 5 years.
  • ABBV had a positive operating cash flow in 4 of the past 5 years.
ABBV Yearly Net Income VS EBIT VS OCF VS FCFABBV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

  • With an excellent Return On Assets value of 1.75%, ABBV belongs to the best of the industry, outperforming 88.29% of the companies in the same industry.
  • ABBV has a Return On Invested Capital of 15.64%. This is amongst the best in the industry. ABBV outperforms 95.97% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ABBV is below the industry average of 18.14%.
  • The 3 year average ROIC (13.67%) for ABBV is below the current ROIC(15.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ABBV Yearly ROA, ROE, ROICABBV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • ABBV has a Profit Margin of 3.94%. This is amongst the best in the industry. ABBV outperforms 88.48% of its industry peers.
  • In the last couple of years the Profit Margin of ABBV has declined.
  • ABBV has a Operating Margin of 33.05%. This is amongst the best in the industry. ABBV outperforms 96.93% of its industry peers.
  • ABBV's Operating Margin has declined in the last couple of years.
  • ABBV's Gross Margin of 71.16% is amongst the best of the industry. ABBV outperforms 82.34% of its industry peers.
  • In the last couple of years the Gross Margin of ABBV has declined.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
ABBV Yearly Profit, Operating, Gross MarginsABBV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ABBV is creating value.
  • ABBV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ABBV Yearly Shares OutstandingABBV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ABBV Yearly Total Debt VS Total AssetsABBV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 2.43 indicates that ABBV is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • ABBV has a Altman-Z score of 2.43. This is in the better half of the industry: ABBV outperforms 66.03% of its industry peers.
  • The Debt to FCF ratio of ABBV is 3.49, which is a good value as it means it would take ABBV, 3.49 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of ABBV (3.49) is better than 92.51% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.43
ROIC/WACC1.91
WACC8.18%
ABBV Yearly LT Debt VS Equity VS FCFABBV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • A Current Ratio of 0.72 indicates that ABBV may have some problems paying its short term obligations.
  • With a Current ratio value of 0.72, ABBV is not doing good in the industry: 88.10% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.60 indicates that ABBV may have some problems paying its short term obligations.
  • The Quick ratio of ABBV (0.60) is worse than 88.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
ABBV Yearly Current Assets VS Current LiabilitesABBV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for ABBV have decreased by -1.19% in the last year.
  • ABBV shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.99% yearly.
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.77% on average over the next years. This is quite good.
  • ABBV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.33% yearly.
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.77%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.33%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
ABBV Yearly Revenue VS EstimatesABBV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
ABBV Yearly EPS VS EstimatesABBV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 23.06, the valuation of ABBV can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of ABBV indicates a rather cheap valuation: ABBV is cheaper than 93.28% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of ABBV to the average of the S&P500 Index (27.11), we can say ABBV is valued inline with the index average.
  • A Price/Forward Earnings ratio of 15.88 indicates a correct valuation of ABBV.
  • Based on the Price/Forward Earnings ratio, ABBV is valued cheaper than 95.59% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ABBV to the average of the S&P500 Index (28.13), we can say ABBV is valued slightly cheaper.
Industry RankSector Rank
PE 23.06
Fwd PE 15.88
ABBV Price Earnings VS Forward Price EarningsABBV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ABBV is valued cheaper than 94.82% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ABBV is valued cheaply inside the industry as 95.59% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.71
EV/EBITDA 16.32
ABBV Per share dataABBV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • ABBV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ABBV has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ABBV's earnings are expected to grow with 21.41% in the coming years.
PEG (NY)0.51
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y21.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 3.04%, ABBV has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.17, ABBV pays a better dividend. On top of this ABBV pays more dividend than 99.04% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.80, ABBV pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.04%

5.2 History

  • The dividend of ABBV is nicely growing with an annual growth rate of 7.72%!
  • ABBV has paid a dividend for at least 10 years, which is a reliable track record.
  • ABBV has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)7.72%
Div Incr Years11
Div Non Decr Years11
ABBV Yearly Dividends per shareABBV Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • ABBV pays out 489.69% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of ABBV is growing, but earnings are growing more, so the dividend growth is sustainable.
DP489.69%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
ABBV Yearly Income VS Free CF VS DividendABBV Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
ABBV Dividend Payout.ABBV Dividend Payout, showing the Payout Ratio.ABBV Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ABBVIE INC

NYSE:ABBV (2/27/2026, 2:05:09 PM)

230.64

+5.95 (+2.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-04
Earnings (Next)04-23
Inst Owners75.04%
Inst Owner Change2.16%
Ins Owners0.05%
Ins Owner Change11.83%
Market Cap407.63B
Revenue(TTM)N/A
Net Income(TTM)2.35B
Analysts77.3
Price Target252.53 (9.49%)
Short Float %1.11%
Short Ratio2.97
Dividend
Industry RankSector Rank
Dividend Yield 3.04%
Yearly Dividend6.24
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years11
Div Non Decr Years11
Ex-Date01-16
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)1.15%
PT rev (3m)1.59%
EPS NQ rev (1m)0.79%
EPS NQ rev (3m)-20.87%
EPS NY rev (1m)0.09%
EPS NY rev (3m)-5.77%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
Industry RankSector Rank
PE 23.06
Fwd PE 15.88
P/S 6.83
P/FCF 20.71
P/OCF 19.54
P/B N/A
P/tB N/A
EV/EBITDA 16.32
EPS(TTM)10
EY4.34%
EPS(NY)14.52
Fwd EY6.3%
FCF(TTM)11.14
FCFY4.83%
OCF(TTM)11.8
OCFY5.12%
SpS33.75
BVpS-1.49
TBVpS-52.38
PEG (NY)0.51
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.43
F-Score7
WACC8.18%
ROIC/WACC1.91
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.33%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year-0.19%
EBIT Next 3Y15.91%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / ABBV FAQ

Can you provide the ChartMill fundamental rating for ABBVIE INC?

ChartMill assigns a fundamental rating of 5 / 10 to ABBV.


What is the valuation status of ABBVIE INC (ABBV) stock?

ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (ABBV). This can be considered as Undervalued.


Can you provide the profitability details for ABBVIE INC?

ABBVIE INC (ABBV) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for ABBV stock?

The Price/Earnings (PE) ratio for ABBVIE INC (ABBV) is 23.06 and the Price/Book (PB) ratio is -154.29.


What is the expected EPS growth for ABBVIE INC (ABBV) stock?

The Earnings per Share (EPS) of ABBVIE INC (ABBV) is expected to grow by 45.22% in the next year.